Dr. Angelos M. Stergiou: Why SELLAS Life Sciences Group is in the News

Dr. Angelos M. Stergiou, MD is the Founder, Chief Executive Officer and Vice Chairman of SELLAS Life Sciences Group.  Angelos Stergiou and his company are changing medicine and science as we know it, and in doing so, they’re potentially saving countless lives.

As the WT1 cancer vaccine trials gain momentum and exposure, Dr. Angelos Stergiou and his team are receiving media attention and international acclaim.

The points below just scratch the surface of this fascinating company that’s pioneering the field of cancer vaccination:

  • Company Overview. SELLAS Life Sciences Group is a biopharmaceutical company that was founded in 2012 by Dr. Stergiou and his colleague, Dr. Miltos K. Sugiultzoglu, MD. It is centered around developing novel cancer therapeutics to save lives and to push cancer vaccination to the next level.

When speaking about the company, Dr. Stergiou was quoted in a 2016 interview stating: “I have always wanted to give back to humanity, and without clinical research, discovery and drug development, we would not have new drugs. The biotechnology sector is a passion of mine. It combines medicine, research and business, and I truly love doing every day.” He continued, saying: “The fact that we are currently developing a cancer vaccine with Memorial Sloan Kettering Cancer Center is very exciting and gets me going.”

  • WT1 Cancer Vaccine. The WT1 cancer vaccine is the most promising oncology product within SELLAS Life Sciences Group. It is named for the WT1 antigen, found in many cancers and few healthy adult cells. It teaches the immune system to seek and destroy the antigen, creating an effective internal response against cancer and recurring tumors. It is among Dr. Stergiou’s biggest accomplishments.

In a recent interview, he stated “We are entering pivotal Phase 3 studies [for the WT1 cancer vaccine] and have an exciting path ahead of us.” In further discussions about the WT1 cancer vaccine, Dr. Angelos Stergiou was quoted saying “The thirst to get to the finish line and get [the WT1 cancer vaccine] approved, so we can potentially save lives, is breathtaking.”

To follow the progression of SELLAS Life Sciences Group and Dr. Angelos M. Stergiou’s team, head to Sellas Life Sciences and keep an eye on happenings around the website. Alternately, stay current with oncology news and you’re sure to see breakthrough trials in the near future.

Also visit: http://sellaslifesciences.com/biopharma/news/

Posted in Angelos Stergiou | Tagged , | Leave a comment

Dr. Angelos Stergiou: Is a Pharmaceutical Career Right for You?

Dr. Angelos M. Stergiou, MD is the Founder, Vice Chairman and CEO of the biopharmaceutical company known as SELLAS Life Sciences Group. In Dr. Stergiou’s own words, “without clinical research, discovery and drug development, we would not have new drugs.” This simple fact has sparked modern interest in pharmaceutical careers.

If the accomplishments and words of pharma experts like Dr. Angelos Stergiou inspire you, it might be time to look further into the field. The information below is a good place to begin:

  • Growing Industry. New medicine is something that the world will always need. The pharmaceutical industry has a consistently-positive industry growth projection and ever-increasing job opportunities for skilled professionals. Furthermore, some countries have trouble filling pharmaceutical positions to capacity, meaning that finding a position in pharma can be easier than finding one in other fields of study.
  • Well-Paying Work. Pharmaceutical positions are well-paying in most countries, typically averaging around thirty-percent higher than national median salary. Though high salaries are always attractive, the projected increase in pharmaceutical pay is an even more attractive prospect.
  • Steady Employment. Medicine is always needed, and pharmaceutical professionals do not suffer the same ups and downs as those in other careers often do. In times of crisis, even, pharmaceuticals are required, and pharma employees are valued.

After nearly 15 years of experience, Dr. Angelos Stergiou, MD is still learning new things, loving his job and pushing his field further. Speaking with respected educational institutions is the first step to joining these professionals in changing the world, improving lives and, hopefully, saving those suffering from disease.

Also read: https://angelosstergiou.wordpress.com/2016/11/03/dr-angelos-stergiou-md-scd-h-c-international-upbringing/

Posted in Angelos Stergiou | Tagged , | Leave a comment

Dr. Angelos M. Stergiou, MD, ScD h.c.: International Upbringing

Dr. Angelos M. Stergiou, MD, ScD h.c. is the Vice Chairman and CEO of SELLAS Life Sciences Group and an international professional. Angelos Stergiou was born and raised in Germany, where his family fought to succeed in the struggling economy. At the age of sixteen, Dr. Angelos moved to the United States to complete high school as an exchange student due to his very good grades in Germany and to eventually begin his university education in the USA.

 

Visit here http://sellaslifesciences.com/management/ to view more detail about Dr. Angelos M. Stergiou.

 

 

Posted in Angelos Stergiou | Tagged ,

Angelos Stergiou – A Conversation with Dr. Angelos M. Stergiou M.D.

Dr. Angelos Stergiou shared his conversation in visit of Kentucky Wesleyan College.

Follow Angelos Stergiou on Twitter: https://twitter.com/drstergiou

Posted in Angelos Stergiou | Tagged | Leave a comment

Angelos Stergiou, MD, ScD h.c.: Combining Work with Pleasure

Dr. Angelos M. Stergiou, MD, ScD h.c. is the Vice Chairman and CEO of SELLAS Life Sciences Group, and pioneering the cancer immunotherapy and cancer vaccination field keeps him busy. He is also, however, a supportive husband. With his wife, Dr. Angelos Stergiou enjoys mixing work with pleasure whenever possible, exploring exciting locales between work obligations in international locations.

Angelos Stergiou also enjoys conversing with her about philosophy, critical thinking and about life in general.

Get connected with Angelos Stergiou through Facebook:  https://www.facebook.com/Angelos-Stergiou-1813027965638555/

Posted in Angelos Stergiou | Tagged , | Leave a comment

Angelos Stergiou: a blend of medicine, research and business

Dr. Angelos M. Stergiou, MD, ScD h.c. is CEO and Vice Chairman of the company behind the WT1 cancer vaccine, SELLAS Life Sciences Group. Prior to founding the company, Dr. Stergiou had worked in a number of positions in biotechnology and pharmaceutical companies in Europe and the United States. Today, he is enjoying his work in the biotechnology sector, a passion of his. In reference to founding SELLAS Life Sciences, he said:

“It combines medicine, research and business, and I truly love doing this every day.” He went on to state: “The thirst to get to the finish line and get [the WT1 cancer vaccine] approved, so we can potentially save lives, is breathtaking.”

Visit https://angelosstergiou.wordpress.com/about-angelos-stergiou to know more bout him.

Posted in Angelos Stergiou | Tagged | Leave a comment

Angelos Stergiou, MD, ScD h.c.: About SELLAS Life Sciences Group

Dr. Angelos M. Stergiou, MD, ScD h.c. is the CEO and Vice Chairman of SELLAS Life Sciences Group, which he founded with the intention to give back to humanity through clinical research, discovery and drug development.

In recent news, Dr. Angelos M. Stergiou and SELLAS Life Sciences Group have received increasing media coverage as the progression of the WT1 neoepitome immunotherapeutic anti-cancer treatment and vaccine continues to yield promising results. The points below will help you learn more about SELLAS Life Sciences Group and what the company is contributing to the world:

  • SELLAS Life Sciences Group. As a leading international biopharmaceutical company, SELLAS Life Sciences focuses on advancing various cancer therapies and developing diverse cancer programs. The company seeks to improve the lives of patients everywhere by commercializing cutting-edge cancer therapeutics.
  • WT1 Neoepitope Immunotherapy. Named for the WT1 antigen – one of the most common antigens found in malignancies – the WT1 anti-cancer treatment, called galinpepimut-S, consists of four synthetically heteroclitically modified peptide chains that are designed to induce patient immune response against the WT1 antigen. As of 2016, trial phases have shown promising survival benefits.

To learn more about the work of SELLAS Life Sciences Group or Dr. Angelos M. Stergiou, MD, visit www.sellaslifesciences.com.

Posted in Angelos Stergiou | Tagged | Leave a comment